IGF-1 LR3 vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
IGF-1 LR3
IGF-1 LR3 (Long Arg3 IGF-1) is a synthetic analogue of Insulin-like Growth Factor 1 with an amino acid substitution at position 3 and a 13-amino acid N-terminal extension. These modifications prevent binding to IGF-binding proteins (IGFBPs), dramatically extending its half-life from ~12 minutes (native IGF-1) to approximately 20–30 hours. IGF-1 LR3 is widely used in research for its ability to promote cellular growth, protein synthesis, hyperplasia, and nutrient uptake into muscle tissue.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| IGF-1 LR3 | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Insulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent) | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol) | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols) | Intramuscular injection, Subcutaneous injection |
| Key side effects | Hypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint pain | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 3 references | 2 references |
Key differences
- Administration: IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols); Triptorelin — Intramuscular injection, Subcutaneous injection.
- Frequency: IGF-1 LR3 is typically Once daily post-workout, on training days only (common protocol); Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
- Research depth: this profile cites 3 sources for IGF-1 LR3 vs 2 for Triptorelin.
How each works
IGF-1 LR3
In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.